lapatinib has been researched along with oxazoles in 5 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (oxazoles) | Trials (oxazoles) | Recent Studies (post-2010) (oxazoles) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 9,281 | 366 | 2,561 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Byun, JY; Cha, MY; Choi, KJ; Jung, YH; Kang, SJ; Kim, MS; Lee, GS; Lee, HJ; Lee, KO; Park, SB; Song, JY | 1 |
| Cao, PR; Huang, W; Kong, YL; Wu, QD; Xu, JH; Ye, M; Zhang, M; Zheng, W | 1 |
| Gelmon, KA; Tesch, ME | 1 |
| Arribas, J; Chandarlapaty, S; de Stanchina, E; Ferraro, E; Kulick, A; Lahuerta, EJA; Li, Q; Morales, CB; Razavi, P; Reis-Filho, J; Rosen, N; Ross, D; Safonov, A; Smith, AE; Solit, DB | 1 |
| Bachelot, T; Bailleux, C; Darlix, A; Jacot, W | 1 |
2 review(s) available for lapatinib and oxazoles
| Article | Year |
|---|---|
Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast; Breast Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Immunoconjugates; Lapatinib; Mastectomy; Maytansine; Medical Oncology; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Oxazoles; Practice Guidelines as Topic; Pyridines; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab | 2020 |
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Cranial Irradiation; Disease Progression; Female; Humans; Lapatinib; Life Expectancy; Magnetic Resonance Imaging; Metastasectomy; Middle Aged; Oxazoles; Pyridines; Quinazolines; Quinolines; Radiosurgery; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab | 2021 |
3 other study(ies) available for lapatinib and oxazoles
| Article | Year |
|---|---|
Synthesis and biological evaluation of pyrimidine-based dual inhibitors of human epidermal growth factor receptor 1 (HER-1) and HER-2 tyrosine kinases.
Topics: Acrylamides; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Mice; Mice, Inbred ICR; Models, Molecular; Mutation; Oxazoles; Pyrimidines; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, ErbB-2; Stomach Neoplasms; Structure-Activity Relationship | 2012 |
Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Immunoenzyme Techniques; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Oxazoles; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway.
Topics: Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; MAP Kinase Signaling System; Mutation; Oxazoles; Protein Kinase Inhibitors; Pyridines; Quinazolines; Quinolines; Receptor, ErbB-2; Tumor Escape | 2021 |